Table 5.
Univariate sensitivity analysis and patient subgroup analysis
| Cost per LYG, € | ||
|---|---|---|
| Scenario 1 ERN/LRPT + simvastatin 40 mg vs simvastatin 40 mg alone |
Scenario 2 ERN/LRPT + simvastatin 20 mg vs simvastatin up-titration |
|
| Base case | 13,331 | 17,684 |
| Time until benefit, 2 years | 14,862 | 19,772 |
| Discount rate, % | ||
| 0 | 11,012 | 14,603 |
| 5 | 15,027 | 19,928 |
| 7 | 16,828 | 22,307 |
| 10 | 19,707 | 26,101 |
| Event costs, % change | ||
| +20 | 13,245 | 17,593 |
| −20 | 13,418 | 17,775 |
| ERN/LRPT costs, % change | ||
| +10 | 14,698 | 19,682 |
| −10 | 11,964 | 15,686 |
| CHD risk, % change | ||
| +20 | 11,599 | 15,326 |
| −20 | 15,940 | 21,234 |
| Simvastatin costs, % change | ||
| −20 | 13,308 | 18,050 |
| ERN/LRPT discontinuation rate owing to flushing | ||
| 7.4% | 13,331 | 18,167 |
| Mean maintenance dose, 1.5 g/day | 11,582 | 15,981 |
| Subgroup analysis | ||
| CHD without diabetes | 15,579 | 20,462 |
| CHD with diabetes | 10,342 | 14,081 |
| Age ≤65 years | 11,783 | 15,680 |
| Age >65 years | 14,704 | 19,119 |
| Low HDL-Ca | 10,749 | 14,283 |
| TC/HDL-C ratio ≥4.5 | 10,696 | 14,176 |
Costs and effects discounted at 3% per annum
CHD Coronary heart disease, ERN extended-release niacin, HDL-C high-density lipoprotein cholesterol, LRPT laropiprant, LYG life-year gained
aLow HDL-C: men, <40 mg/dL; women, <45 mg/dL